The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

  1. StudyEvent: SEV1
    1. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    2. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    3. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    9. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    10. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. Subject - Consent Information
    15. Subject - Sample Mapping (including mapping to Coriell IDs)
    16. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    17. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
pht000374.v2.p1
Descrição

pht000374.v2.p1

DUMMY ID NUMBER
Descrição

ID2

Tipo de dados

string

TYPE OF CANCER (ALL PARTICIPANTS)
Descrição

NDCANCTP

Tipo de dados

string

STUDY VISIT NUMBER (ALL PARTICIPANTS)
Descrição

VISNO

Tipo de dados

text

NEW DIAGNOSIS OF CANCER SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
Descrição

NDCANC

Tipo de dados

text

NEW DIAGNOSIS OF HEART DISEASE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
Descrição

NDHEART

Tipo de dados

text

NEW DIAGNOSIS OF STROKE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
Descrição

NDSTROK

Tipo de dados

text

NEW DIAGNOSIS OF PERIPHERAL VASCULAR DISEASE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
Descrição

NDVASC

Tipo de dados

text

CATARACT SURGERY - RIGHT EYE (ALL PARTICIPANTS)
Descrição

CATSRGRE

Tipo de dados

text

CATARACT SURGERY - LEFT EYE (ALL PARTICIPANTS)
Descrição

CATSRGLE

Tipo de dados

text

LENS PRESENT - RIGHT EYE (ALL PARTICIPANTS)
Descrição

LNSPRSRE

Tipo de dados

text

LENS PRESENT - LEFT EYE (ALL PARTICIPANTS)
Descrição

LNSPRSLE

Tipo de dados

text

LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - RIGHT EYE (ALL PARTICIPANTS)
Descrição

AMDTRTRE

Tipo de dados

text

LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - LEFT EYE (ALL PARTICIPANTS)
Descrição

AMDTRTLE

Tipo de dados

text

INTRA-OCULAR PRESSURE (IOP) RIGHT EYE (MMHG) (ALL PARTICIPANTS)
Descrição

IOPRE

Tipo de dados

text

INTRA-OCULAR PRESSURE (IOP) LEFT EYE (MMHG) (ALL PARTICIPANTS)
Descrição

IOPLE

Tipo de dados

text

VISUAL ACUITY - RIGHT EYE (ALL PARTICIPANTS)
Descrição

FOLLVARE

Tipo de dados

text

VISUAL ACUITY - LEFT EYE (ALL PARTICIPANTS)
Descrição

FOLLVALE

Tipo de dados

text

REFRACTIVE ERROR - RIGHT EYE (ALL PARTICIPANTS)
Descrição

RE_ERR_F

Tipo de dados

float

REFRACTIVE ERROR - LEFT EYE (ALL PARTICIPANTS)
Descrição

LE_ERR_F

Tipo de dados

float

LAST VISIT OF CLINICAL TRIAL (ALL PARTICIPANTS)
Descrição

EOTVIS

Tipo de dados

text

CURRENTLY HAVE ARTHRITIS (ALL PARTICIPANTS)
Descrição

ARTHRIT

Tipo de dados

text

CURRENTLY HAVE GOUT (ALL PARTICIPANTS)
Descrição

GOUT

Tipo de dados

text

CURRENTLY HAVE DIABETES (ALL PARTICIPANTS)
Descrição

DIABETES

Tipo de dados

text

HISTORY OF GLAUCOMA (ALL PARTICIPANTS)
Descrição

GLAUCOMA

Tipo de dados

text

GLAUCOMA SURGERY - RIGHT EYE (ALL PARTICIPANTS)
Descrição

GLASRGRE

Tipo de dados

text

GLAUCOMA SURGERY - LEFT EYE (ALL PARTICIPANTS)
Descrição

GLASRGLE

Tipo de dados

text

NON-AMD SURGERIES - RIGHT EYE (ALL PARTICIPANTS)
Descrição

ANYEYERE

Tipo de dados

text

NON-AMD SURGERIES - LEFT EYE (ALL PARTICIPANTS)
Descrição

ANYEYELE

Tipo de dados

text

CAPSULOTOMY - RIGHT EYE (ALL PARTICIPANTS)
Descrição

CAPSULRE

Tipo de dados

text

CAPSULOTOMY - LEFT EYE (ALL PARTICIPANTS)
Descrição

CAPSULLE

Tipo de dados

text

REPAIR RETINAL - RIGHT EYE (ALL PARTICIPANTS)
Descrição

REPRETRE

Tipo de dados

text

REPAIR RETINAL - LEFT EYE (ALL PARTICIPANTS)
Descrição

REPRETLE

Tipo de dados

text

OTHER SURGERY - RIGHT EYE (ALL PARTICIPANTS)
Descrição

OCUSRGRE

Tipo de dados

text

OTHER SURGERY - LEFT EYE (ALL PARTICIPANTS)
Descrição

OCUSRGLE

Tipo de dados

text

OTHER SURGERY DESCRIPTION - RIGHT EYE (ALL PARTICIPANTS)
Descrição

VOTSRGRE

Tipo de dados

string

OTHER SURGERY DESCRIPTION - LEFT EYE (ALL PARTICIPANTS)
Descrição

VOTSRGLE

Tipo de dados

string

MEDICATIONS TO CONTROL EYE PRESSURE (ALL PARTICIPANTS)
Descrição

GLAMEDS

Tipo de dados

text

FOLLOW-UP INTERVIEW TYPE (ALL PARTICIPANTS)
Descrição

FOLUPINT

Tipo de dados

text

YEARS TAKING HYDROCHLOROTHIAZIDE (ALL PARTICIPANTS)
Descrição

HYDROCH5

Tipo de dados

text

YEARS TAKING DIPYRIDAMOLE (ALL PARTICIPANTS)
Descrição

DIPYRID5

Tipo de dados

text

YEARS TAKING TRIAMTERENE (ALL PARTICIPANTS)
Descrição

TRIAMTE5

Tipo de dados

text

YEARS TAKING SPIRONOLACTONE (ALL PARTICIPANTS)
Descrição

SPIRONO5

Tipo de dados

text

YEARS TAKING PROPRANOLOL (ALL PARTICIPANTS)
Descrição

PROPRAN5

Tipo de dados

text

YEARS TAKING OTHER BETA-BLOCKER (ALL PARTICIPANTS)
Descrição

BETABLO5

Tipo de dados

text

YEARS TAKING CHLORTHALIDONE (ALL PARTICIPANTS)
Descrição

CHLORTH5

Tipo de dados

text

YEARS TAKING FUROSEMIDE (ALL PARTICIPANTS)
Descrição

FUROSEM5

Tipo de dados

text

YEARS TAKING ACE INHIBITORS (ALL PARTICIPANTS)
Descrição

ACEINHI5

Tipo de dados

text

YEARS TAKING CALCIUM CHANNEL BLOCKERS (ALL PARTICIPANTS)
Descrição

CALCBLO5

Tipo de dados

text

YEARS TAKING POTASSIUM CHLORIDE (ALL PARTICIPANTS)
Descrição

POTASSI5

Tipo de dados

text

YEARS TAKING DIGOXIN (ALL PARTICIPANTS)
Descrição

DIGOXIN5

Tipo de dados

text

YEARS TAKING NITROGLYCERIN (ALL PARTICIPANTS)
Descrição

NITROGL5

Tipo de dados

text

YEARS TAKING ISOBIDE DINITRATE (ALL PARTICIPANTS)
Descrição

ISOBDIN5

Tipo de dados

text

YEARS TAKING ALLOPURINOL (ALL PARTICIPANTS)
Descrição

ALLOPUR5

Tipo de dados

text

YEARS TAKING BENEMID (ALL PARTICIPANTS)
Descrição

BENEMID5

Tipo de dados

text

YEARS TAKING BLOOD THINNING MEDICATION (ALL PARTICIPANTS)
Descrição

BLOODTH5

Tipo de dados

text

YEARS TAKING MEDICATION TO LOWER CHOLESTEROL OR LIPIDS (ALL PARTICIPANTS)
Descrição

LOWRCHO5

Tipo de dados

text

YEARS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUG (ALL PARTICIPANTS)
Descrição

ANTIINF5

Tipo de dados

text

YEARS TAKING THYROID HORMONES (ALL PARTICIPANTS)
Descrição

THYRHOR5

Tipo de dados

text

YEARS EVER TAKEN ASPIRIN OR ASPIRIN PRODUCTS (ALL PARTICIPANTS)
Descrição

ASPIRIN5

Tipo de dados

text

CURRENTLY TAKING ASPIRIN (ALL PARTICIPANTS)
Descrição

ASPICUR5

Tipo de dados

text

YEARS EVER TAKEN ACETAMINOPHEN/TYLENOL (ALL PARTICIPANTS)
Descrição

ACETAMI5

Tipo de dados

text

CURRENTLY TAKING ACETAMINOPHEN/TYLENOL (ALL PARTICIPANTS)
Descrição

ACETCUR5

Tipo de dados

text

SITTING SYSTOLIC BLOOD PRESSURE (ALL PARTICIPANTS)
Descrição

SITSYS15

Tipo de dados

text

SITTING DIASTOLIC BLOOD PRESSURE (ALL PARTICIPANTS)
Descrição

SITDIA15

Tipo de dados

text

EVER SMOKED CIGARETTES FOR 6 MONTHS OR MORE (ALL PARTICIPANTS)
Descrição

SMOKEDY5

Tipo de dados

text

AGE STARTED SMOKING (ALL PARTICIPANTS)
Descrição

SMKAGES5

Tipo de dados

text

AVERAGE PACKS PER DAY SMOKED (ALL PARTICIPANTS)
Descrição

SMKPACK5

Tipo de dados

text

CURRENTLY SMOKE (ALL PARTICIPANTS)
Descrição

SMKCURR5

Tipo de dados

text

HOW MANY CIGARETTES PER DAY SMOKE (ALL PARTICIPANTS)
Descrição

SMKNOCI5

Tipo de dados

text

AGE QUIT SMOKING (ALL PARTICIPANTS)
Descrição

SMKAGEQ5

Tipo de dados

text

HISTORY OF HIGH BLOOD PRESSURE (ALL PARTICIPANTS)
Descrição

BPHIGHY5

Tipo de dados

text

CURRENTLY TAKING MEDICATION FOR HIGH BLOOD PRESSURE (ALL PARTICIPANTS)
Descrição

BPMEDNO5

Tipo de dados

text

HISTORY OF ANGINA (ALL PARTICIPANTS)
Descrição

ANGINAY5

Tipo de dados

text

SITTING SYSTOLIC BLOOD PRESSURE (2ND READING) (ALL PARTICIPANTS)
Descrição

SITSYS25

Tipo de dados

text

SITTING DIASTOLIC BLOOD PRESSURE (2ND READING) (ALL PARTICIPANTS)
Descrição

SITDIA25

Tipo de dados

text

BODY-MASS INDEX (ALL PARTICIPANTS)
Descrição

BMI5

Tipo de dados

float

STUDY TREATMENT ARM AT VISIT (ALL PARTICIPANTS)
Descrição

FOLLTRT

Tipo de dados

text

YEARS FROM RANDOMIZATION TO DATE OF STUDY VISIT (ALL PARTICIPANTS)
Descrição

VISTIME

Tipo de dados

float

YEARS FROM RANDOMIZATION TO DATE OF CATARACT SURGERY - RIGHT EYE (ALL PARTICIPANTS)
Descrição

CATRETIME

Tipo de dados

float

YEARS FROM RANDOMIZATION TO DATE OF CATARACT SURGERY - LEFT EYE (ALL PARTICIPANTS)
Descrição

CATLETIME

Tipo de dados

float

YEARS FROM RANDOMIZATION TO LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - RIGHT EYE (ALL PARTICIPANTS)
Descrição

AMDTRTRETIME

Tipo de dados

float

YEARS FROM RANDOMIZATION TO LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - LEFT EYE (ALL PARTICIPANTS)
Descrição

AMDTRTLETIME

Tipo de dados

float

YEARS FROM RANDOMIZATION TO DATE OF FOLLOW-UP INTERVIEW (ALL PARTICIPANTS)
Descrição

FOLTIME

Tipo de dados

float

Similar models

The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

  1. StudyEvent: SEV1
    1. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    2. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    3. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    9. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    10. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. Subject - Consent Information
    15. Subject - Sample Mapping (including mapping to Coriell IDs)
    16. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    17. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
pht000374.v2.p1
ID2
Item
DUMMY ID NUMBER
string
NDCANCTP
Item
TYPE OF CANCER (ALL PARTICIPANTS)
string
Item
STUDY VISIT NUMBER (ALL PARTICIPANTS)
text
Code List
STUDY VISIT NUMBER (ALL PARTICIPANTS)
CL Item
Baseline visit (00)
CL Item
0.5-year (01)
CL Item
1-year (02)
CL Item
1.5-years (03)
CL Item
2-years (04)
CL Item
2.5-years (05)
CL Item
3-years (06)
CL Item
3.5-years (07)
CL Item
4-years (08)
CL Item
4.5-years (09)
CL Item
5-years (10)
CL Item
5.5-years (11)
CL Item
6-years (12)
CL Item
6.5-years (13)
CL Item
7-years (14)
CL Item
7.5-years (15)
CL Item
8-years (16)
CL Item
8.5-years (17)
CL Item
9-years (18)
CL Item
9.5-years (19)
CL Item
10-years (20)
CL Item
10.5-years (21)
CL Item
11-years (22)
CL Item
11.5-years (23)
CL Item
12-years (24)
CL Item
12.5-years (25)
CL Item
13-years (26)
Item
NEW DIAGNOSIS OF CANCER SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
text
Code List
NEW DIAGNOSIS OF CANCER SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
NEW DIAGNOSIS OF HEART DISEASE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
text
Code List
NEW DIAGNOSIS OF HEART DISEASE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
NEW DIAGNOSIS OF STROKE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
text
Code List
NEW DIAGNOSIS OF STROKE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
NEW DIAGNOSIS OF PERIPHERAL VASCULAR DISEASE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
text
Code List
NEW DIAGNOSIS OF PERIPHERAL VASCULAR DISEASE SINCE LAST STUDY VISIT (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CATARACT SURGERY - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
CATARACT SURGERY - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CATARACT SURGERY - LEFT EYE (ALL PARTICIPANTS)
text
Code List
CATARACT SURGERY - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
LENS PRESENT - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
LENS PRESENT - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
LENS PRESENT - LEFT EYE (ALL PARTICIPANTS)
text
Code List
LENS PRESENT - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Questionable (Q)
CL Item
Yes (Y)
Item
LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - LEFT EYE (ALL PARTICIPANTS)
text
Code List
LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Questionable (Q)
CL Item
Yes (Y)
IOPRE
Item
INTRA-OCULAR PRESSURE (IOP) RIGHT EYE (MMHG) (ALL PARTICIPANTS)
text
IOPLE
Item
INTRA-OCULAR PRESSURE (IOP) LEFT EYE (MMHG) (ALL PARTICIPANTS)
text
FOLLVARE
Item
VISUAL ACUITY - RIGHT EYE (ALL PARTICIPANTS)
text
FOLLVALE
Item
VISUAL ACUITY - LEFT EYE (ALL PARTICIPANTS)
text
RE_ERR_F
Item
REFRACTIVE ERROR - RIGHT EYE (ALL PARTICIPANTS)
float
LE_ERR_F
Item
REFRACTIVE ERROR - LEFT EYE (ALL PARTICIPANTS)
float
Item
LAST VISIT OF CLINICAL TRIAL (ALL PARTICIPANTS)
text
Code List
LAST VISIT OF CLINICAL TRIAL (ALL PARTICIPANTS)
CL Item
Yes (Y)
Item
CURRENTLY HAVE ARTHRITIS (ALL PARTICIPANTS)
text
Code List
CURRENTLY HAVE ARTHRITIS (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CURRENTLY HAVE GOUT (ALL PARTICIPANTS)
text
Code List
CURRENTLY HAVE GOUT (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CURRENTLY HAVE DIABETES (ALL PARTICIPANTS)
text
Code List
CURRENTLY HAVE DIABETES (ALL PARTICIPANTS)
CL Item
Yes, diet treatment (D)
CL Item
Yes, insulin treatment (I)
CL Item
No (N)
CL Item
Yes, pill treatment (P)
Item
HISTORY OF GLAUCOMA (ALL PARTICIPANTS)
text
Code List
HISTORY OF GLAUCOMA (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Suspected (S)
CL Item
Yes (Y)
Item
GLAUCOMA SURGERY - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
GLAUCOMA SURGERY - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
GLAUCOMA SURGERY - LEFT EYE (ALL PARTICIPANTS)
text
Code List
GLAUCOMA SURGERY - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
NON-AMD SURGERIES - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
NON-AMD SURGERIES - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
NON-AMD SURGERIES - LEFT EYE (ALL PARTICIPANTS)
text
Code List
NON-AMD SURGERIES - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CAPSULOTOMY - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
CAPSULOTOMY - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CAPSULOTOMY - LEFT EYE (ALL PARTICIPANTS)
text
Code List
CAPSULOTOMY - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
REPAIR RETINAL - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
REPAIR RETINAL - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
REPAIR RETINAL - LEFT EYE (ALL PARTICIPANTS)
text
Code List
REPAIR RETINAL - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
OTHER SURGERY - RIGHT EYE (ALL PARTICIPANTS)
text
Code List
OTHER SURGERY - RIGHT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
OTHER SURGERY - LEFT EYE (ALL PARTICIPANTS)
text
Code List
OTHER SURGERY - LEFT EYE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
VOTSRGRE
Item
OTHER SURGERY DESCRIPTION - RIGHT EYE (ALL PARTICIPANTS)
string
VOTSRGLE
Item
OTHER SURGERY DESCRIPTION - LEFT EYE (ALL PARTICIPANTS)
string
Item
MEDICATIONS TO CONTROL EYE PRESSURE (ALL PARTICIPANTS)
text
Code List
MEDICATIONS TO CONTROL EYE PRESSURE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
FOLLOW-UP INTERVIEW TYPE (ALL PARTICIPANTS)
text
Code List
FOLLOW-UP INTERVIEW TYPE (ALL PARTICIPANTS)
CL Item
5-year visit (1)
CL Item
Last Clinical Trial visit (2)
CL Item
10-year visit (3)
CL Item
Last Study visit (4)
Item
YEARS TAKING HYDROCHLOROTHIAZIDE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING HYDROCHLOROTHIAZIDE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING DIPYRIDAMOLE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING DIPYRIDAMOLE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING TRIAMTERENE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING TRIAMTERENE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING SPIRONOLACTONE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING SPIRONOLACTONE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING PROPRANOLOL (ALL PARTICIPANTS)
text
Code List
YEARS TAKING PROPRANOLOL (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING OTHER BETA-BLOCKER (ALL PARTICIPANTS)
text
Code List
YEARS TAKING OTHER BETA-BLOCKER (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING CHLORTHALIDONE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING CHLORTHALIDONE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING FUROSEMIDE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING FUROSEMIDE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING ACE INHIBITORS (ALL PARTICIPANTS)
text
Code List
YEARS TAKING ACE INHIBITORS (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING CALCIUM CHANNEL BLOCKERS (ALL PARTICIPANTS)
text
Code List
YEARS TAKING CALCIUM CHANNEL BLOCKERS (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING POTASSIUM CHLORIDE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING POTASSIUM CHLORIDE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING DIGOXIN (ALL PARTICIPANTS)
text
Code List
YEARS TAKING DIGOXIN (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING NITROGLYCERIN (ALL PARTICIPANTS)
text
Code List
YEARS TAKING NITROGLYCERIN (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING ISOBIDE DINITRATE (ALL PARTICIPANTS)
text
Code List
YEARS TAKING ISOBIDE DINITRATE (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING ALLOPURINOL (ALL PARTICIPANTS)
text
Code List
YEARS TAKING ALLOPURINOL (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING BENEMID (ALL PARTICIPANTS)
text
Code List
YEARS TAKING BENEMID (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING BLOOD THINNING MEDICATION (ALL PARTICIPANTS)
text
Code List
YEARS TAKING BLOOD THINNING MEDICATION (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING MEDICATION TO LOWER CHOLESTEROL OR LIPIDS (ALL PARTICIPANTS)
text
Code List
YEARS TAKING MEDICATION TO LOWER CHOLESTEROL OR LIPIDS (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUG (ALL PARTICIPANTS)
text
Code List
YEARS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUG (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS TAKING THYROID HORMONES (ALL PARTICIPANTS)
text
Code List
YEARS TAKING THYROID HORMONES (ALL PARTICIPANTS)
CL Item
Not taking (0)
CL Item
Less than 5 years (1)
CL Item
Equal to or more than 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
YEARS EVER TAKEN ASPIRIN OR ASPIRIN PRODUCTS (ALL PARTICIPANTS)
text
Code List
YEARS EVER TAKEN ASPIRIN OR ASPIRIN PRODUCTS (ALL PARTICIPANTS)
CL Item
Never (0)
CL Item
Less than 5 years (1)
CL Item
More than or equal to 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
CURRENTLY TAKING ASPIRIN (ALL PARTICIPANTS)
text
Code List
CURRENTLY TAKING ASPIRIN (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
YEARS EVER TAKEN ACETAMINOPHEN/TYLENOL (ALL PARTICIPANTS)
text
Code List
YEARS EVER TAKEN ACETAMINOPHEN/TYLENOL (ALL PARTICIPANTS)
CL Item
Never (0)
CL Item
Less than 5 years (1)
CL Item
More than or equal to 5 and less than 10 years (2)
CL Item
More than or equal to 10 and less than 20 years (3)
CL Item
More than or equal to 20 years (4)
Item
CURRENTLY TAKING ACETAMINOPHEN/TYLENOL (ALL PARTICIPANTS)
text
Code List
CURRENTLY TAKING ACETAMINOPHEN/TYLENOL (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
SITSYS15
Item
SITTING SYSTOLIC BLOOD PRESSURE (ALL PARTICIPANTS)
text
SITDIA15
Item
SITTING DIASTOLIC BLOOD PRESSURE (ALL PARTICIPANTS)
text
Item
EVER SMOKED CIGARETTES FOR 6 MONTHS OR MORE (ALL PARTICIPANTS)
text
Code List
EVER SMOKED CIGARETTES FOR 6 MONTHS OR MORE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
SMKAGES5
Item
AGE STARTED SMOKING (ALL PARTICIPANTS)
text
Item
AVERAGE PACKS PER DAY SMOKED (ALL PARTICIPANTS)
text
Code List
AVERAGE PACKS PER DAY SMOKED (ALL PARTICIPANTS)
CL Item
Less than or equal to 0.5 pack (1)
CL Item
More than 0.5, less than or equal to 1 pack (2)
CL Item
More than 1, less than or equal to 2 packs (3)
CL Item
More than 2 packs (4)
Item
CURRENTLY SMOKE (ALL PARTICIPANTS)
text
Code List
CURRENTLY SMOKE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
SMKNOCI5
Item
HOW MANY CIGARETTES PER DAY SMOKE (ALL PARTICIPANTS)
text
SMKAGEQ5
Item
AGE QUIT SMOKING (ALL PARTICIPANTS)
text
Item
HISTORY OF HIGH BLOOD PRESSURE (ALL PARTICIPANTS)
text
Code List
HISTORY OF HIGH BLOOD PRESSURE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
CURRENTLY TAKING MEDICATION FOR HIGH BLOOD PRESSURE (ALL PARTICIPANTS)
text
Code List
CURRENTLY TAKING MEDICATION FOR HIGH BLOOD PRESSURE (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
HISTORY OF ANGINA (ALL PARTICIPANTS)
text
Code List
HISTORY OF ANGINA (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
SITSYS25
Item
SITTING SYSTOLIC BLOOD PRESSURE (2ND READING) (ALL PARTICIPANTS)
text
SITDIA25
Item
SITTING DIASTOLIC BLOOD PRESSURE (2ND READING) (ALL PARTICIPANTS)
text
BMI5
Item
BODY-MASS INDEX (ALL PARTICIPANTS)
float
Item
STUDY TREATMENT ARM AT VISIT (ALL PARTICIPANTS)
text
Code List
STUDY TREATMENT ARM AT VISIT (ALL PARTICIPANTS)
CL Item
Placebo (1)
CL Item
Antioxidants (2)
CL Item
Zinc (3)
CL Item
Antioxidants+Zinc (4)
VISTIME
Item
YEARS FROM RANDOMIZATION TO DATE OF STUDY VISIT (ALL PARTICIPANTS)
float
CATRETIME
Item
YEARS FROM RANDOMIZATION TO DATE OF CATARACT SURGERY - RIGHT EYE (ALL PARTICIPANTS)
float
CATLETIME
Item
YEARS FROM RANDOMIZATION TO DATE OF CATARACT SURGERY - LEFT EYE (ALL PARTICIPANTS)
float
AMDTRTRETIME
Item
YEARS FROM RANDOMIZATION TO LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - RIGHT EYE (ALL PARTICIPANTS)
float
AMDTRTLETIME
Item
YEARS FROM RANDOMIZATION TO LASER PHOTOCOAGULATION OR PHOTODYNAMIC THERAPY FOR AMD SRNV - LEFT EYE (ALL PARTICIPANTS)
float
FOLTIME
Item
YEARS FROM RANDOMIZATION TO DATE OF FOLLOW-UP INTERVIEW (ALL PARTICIPANTS)
float